Search results
Showing 121 to 135 of 333 results for medicines & devices medicine & health
Unintentional injuries: prevention strategies for under 15s (PH29)
This guideline covers strategies, regulation, enforcement, surveillance and workforce development in relation to preventing unintentional injuries in the home, on the road and during outdoor play and leisure.
Immunosuppressive therapy for kidney transplant in adults (TA481)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Biographies and registered interests for members of the Technology Appraisal Committee A
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them. News 04 June 2026 NICE issues new...
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs